To evaluate the use of WBC miR-155-5p as a molecular biomarker for the assessment of cancer risk in CF-BRCA1 methylation-carrying females, we measured the level of WBC miR-155-5p in ten BRCA1-methylation carriers, as used in our previous study [39]. This evidence concerns the gene BRCA1 and cancer.